Cabell Christopher
SEC insider (Form 3/4/5 filer). CIK 0001814928. President & Head of R&D at Inhibikase Therapeutics, Inc. (IKT). 4 reported Form 4/5 transactions since Sep 2024; latest on Feb 21, 2026. Located in WILMINGTON, DE.
Companies Cabell Christopher has filed insider reports for
- Inhibikase Therapeutics, Inc. (IKT): Officer, President & Head of R&D
Cabell Christopher
CIK: 0001814928
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Inhibikase Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Feb 21, 2026IKT
Inhibikase Therapeutics, Inc.
DispositionDirect338.3K shares- - Jan 5, 2026IKT
Inhibikase Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
900.1K shares- - Feb 21, 2025IKT
Inhibikase Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
1.1M shares- - Feb 21, 2025IKT
Inhibikase Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
1.1M shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 21, 2026 | IKT Inhibikase Therapeutics, Inc. | Disposition | 338,282 | - | $0 | Direct |
| Jan 5, 2026 | IKT Inhibikase Therapeutics, Inc. | Award Stock Option (Right to Buy) | 900,117 | - | - | Direct |
| Feb 21, 2025 | IKT Inhibikase Therapeutics, Inc. | Award Stock Option (Right to Buy) | 1,100,705 | - | - | Direct |
| Feb 21, 2025 | IKT Inhibikase Therapeutics, Inc. | Award Stock Option (Right to Buy) | 1,100,705 | - | - | Direct |
1-4 of 4 transactions